What Is Rasagiline Mesylate?

Rasagiline mesylate is a selective, irreversible monoamine oxidase-B (MAO-B) inhibitor that plays a central role in the management of Parkinson's disease (PD). Its primary mechanism involves inhibiting the breakdown of dopamine by MAO-B within the central nervous system, thereby enhancing synaptic dopamine concentrations in the striatum. This pharmacological action directly addresses the dopaminergic deficit characteristic of PD. With approximately 14-fold greater selectivity for MAO-B over MAO-A, rasagiline offers a targeted and safer profile, minimizing hypertensive crises associated with dietary tyramine ("cheese effect").

Alfa Chemistry provides pharmaceutical-grade rasagiline mesylate, a white to off-white crystalline powder with high solubility in water, ethanol, and DMSO, suitable for formulation and bioavailability studies.

How Is Rasagiline Mesylate Used in Parkinson's Disease?

Rasagiline mesylate is used as monotherapy in the initial stages of Parkinson's disease and as an adjunct to levodopa in later stages of the disease. In early PD, rasagiline mesylate has been shown to slow disease progression and improve motor performance. Its use as an add-on therapy has demonstrated significant reductions in "off" time and improved "on" time without troublesome dyskinesia. In a multicenter, double-blind, placebo-controlled trial, fluctuating Parkinson's patients receiving either 0.5, 1 or 2 mg/day of rasagiline experienced a 23% reduction in Unified Parkinson's Disease Rating Scale (UPDRS) scores versus 8.5% in the placebo group^[2]. The effect lasted up to 6 weeks post-treatment, suggesting a long-lasting effect of the compound. Rasagiline mesylate also maintained a benign side effect profile with adverse events similar to placebo.

What Are the Neuroprotective Effects of Rasagiline Mesylate?

Beyond symptomatic relief, rasagiline mesylate exerts significant neuroprotective effects. It prevents the dissipation of mitochondrial membrane potential and activates key signaling pathways such as the PKC-MAP kinase cascade, which are essential in neuronal survival. It also modulates apoptotic regulators by upregulating anti-apoptotic proteins like Bcl-2 and downregulating pro-apoptotic proteins such as Bax. Intriguingly, its metabolic byproducts—particularly aminoindan derivatives—demonstrate additional neuroprotective activity by enhancing mitochondrial function and reducing oxidative stress. These properties potentially position rasagiline as a disease-modifying agent rather than a purely symptomatic one.

How Does Rasagiline Mesylate Compare to Other MAO Inhibitors?

A major differentiating feature of rasagiline mesylate, compared to older MAO inhibitors such as selegiline, is its lack of amphetamine-like metabolites, which reduces the risk of insomnia, agitation, and cardiovascular stimulation. Additionally, the chemical structure also results in a longer half-life of MAO-B inhibition and better pharmacokinetics (fast absorption and increased biotransformation by the liver, without food interference).

What Are the Known Adverse Effects and Drug Interactions?

Rasagiline mesylate is generally well tolerated. Common side effects include gastrointestinal disturbances (nausea, dry mouth, constipation), CNS effects (dizziness, somnolence, insomnia, hallucinations), cardiovascular symptoms (orthostatic hypotension, palpitations), and psychiatric disturbances (impulse control disorders, depression). When co-administered with levodopa, synergistic effects on dopamine levels can enhance both therapeutic benefit and dopaminergic side effects. However, rasagiline does not exacerbate hypertensive crises when consumed with tyramine-rich foods, unlike non-selective MAO inhibitors.

The compound is metabolized predominantly in the liver and excreted via urine. It is contraindicated in patients on meperidine, tramadol, or other MAO inhibitors due to serotonin syndrome risk.